These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 27109894)

  • 21. Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside.
    Palandri C; Santini L; Argirò A; Margara F; Doste R; Bueno-Orovio A; Olivotto I; Coppini R
    Drugs; 2022 Jun; 82(8):889-912. PubMed ID: 35696053
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiarrhythmic agent cibenzoline attenuates latent obstruction in the left ventricular outflow tract of hypertrophic cardiomyopathy.
    Nomura T; Kojima A; Urakabe Y; Enomoto-Uemura S; Nishikawa S; Keira N; Matsubara H; Tatsumi T
    Int J Cardiol; 2011 May; 148(3):359-61. PubMed ID: 20888654
    [No Abstract]   [Full Text] [Related]  

  • 23. Late sodium current inhibitors to treat exercise-induced obstruction in hypertrophic cardiomyopathy: an in vitro study in human myocardium.
    Ferrantini C; Pioner JM; Mazzoni L; Gentile F; Tosi B; Rossi A; Belardinelli L; Tesi C; Palandri C; Matucci R; Cerbai E; Olivotto I; Poggesi C; Mugelli A; Coppini R
    Br J Pharmacol; 2018 Jul; 175(13):2635-2652. PubMed ID: 29579779
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacotherapy for the treatment of obstructive hypertrophic cardiomyopathy.
    Spoladore R; Fragasso G; Pannone L; Slavich M; Margonato A
    Expert Opin Pharmacother; 2020 Feb; 21(2):233-242. PubMed ID: 31893930
    [No Abstract]   [Full Text] [Related]  

  • 25. [Drug treatment for chronic heart failure with reduced ejection fraction].
    Rickenbacher P
    Ther Umsch; 2011 Feb; 68(2):71-9. PubMed ID: 21271537
    [TBL] [Abstract][Full Text] [Related]  

  • 26. End-stage hypertrophic cardiomyopathy in a cat.
    White AJ
    Can Vet J; 2015 May; 56(5):509-11. PubMed ID: 25969586
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term survival in patients with resting obstructive hypertrophic cardiomyopathy comparison of conservative versus invasive treatment.
    Ball W; Ivanov J; Rakowski H; Wigle ED; Linghorne M; Ralph-Edwards A; Williams WG; Schwartz L; Guttman A; Woo A
    J Am Coll Cardiol; 2011 Nov; 58(22):2313-21. PubMed ID: 22093509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The 50-year history, controversy, and clinical implications of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy: from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy.
    Maron BJ; Maron MS; Wigle ED; Braunwald E
    J Am Coll Cardiol; 2009 Jul; 54(3):191-200. PubMed ID: 19589431
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypertrophic cardiomyopathy in childhood and adolescence - strategies to prevent sudden death.
    Ostman-Smith I
    Fundam Clin Pharmacol; 2010 Oct; 24(5):637-52. PubMed ID: 20727015
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A primer of disopyramide treatment of obstructive hypertrophic cardiomyopathy.
    Sherrid MV; Arabadjian M
    Prog Cardiovasc Dis; 2012; 54(6):483-92. PubMed ID: 22687589
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy.
    Sherrid MV; Barac I; McKenna WJ; Elliott PM; Dickie S; Chojnowska L; Casey S; Maron BJ
    J Am Coll Cardiol; 2005 Apr; 45(8):1251-8. PubMed ID: 15837258
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Arrhythmic syndrome and sudden death in hypertrophic cardiomyopathy].
    Storozhakov GI; Selivanov AI; Kisliak OA
    Ter Arkh; 1988; 60(8):137-41. PubMed ID: 2906486
    [No Abstract]   [Full Text] [Related]  

  • 33. [The QTc interval and its dispersion in hypertrophic myocardiopathy--its relation to complex ventricular arrhythmias and the effect of anti-arrhythmia agents].
    Sousa MJ; Aranha J; Cotrim C; Sousa L; Sequeira A; Soares RM; Abreu J; Bernardes L; Gracias R; Salomão S
    Rev Port Cardiol; 1995 Jun; 14(6):461-7, 447-8. PubMed ID: 7662385
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drugs for chronic heart failure.
    Med Lett Drugs Ther; 1996 Oct; 38(985):92-4. PubMed ID: 8874393
    [No Abstract]   [Full Text] [Related]  

  • 35. Aficamten: A Breakthrough Therapy for Symptomatic Obstructive Hypertrophic Cardiomyopathy.
    Sebastian SA; Padda I; Lehr EJ; Johal G
    Am J Cardiovasc Drugs; 2023 Sep; 23(5):519-532. PubMed ID: 37526885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypertension Management in Transition: From CKD to ESRD.
    Valika A; Peixoto AJ
    Adv Chronic Kidney Dis; 2016 Jul; 23(4):255-61. PubMed ID: 27324679
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of Patient Characteristics and Course of Hypertensive Hypokinetic Cardiomyopathy Versus Idiopathic Dilated Cardiomyopathy.
    Bobbo M; Pinamonti B; Merlo M; Stolfo D; Iorio A; Ramani F; Barbati G; Carriere C; Massa L; Poli S; Scapol S; Gigli M; Di Lenarda A; Sinagra G
    Am J Cardiol; 2017 Feb; 119(3):483-489. PubMed ID: 27988039
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disopyramide for Hypertrophic Cardiomyopathy: A Pragmatic Reappraisal of an Old Drug.
    Verlinden NJ; Coons JC
    Pharmacotherapy; 2015 Dec; 35(12):1164-72. PubMed ID: 26684556
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis.
    Psaty BM; Lumley T; Furberg CD; Schellenbaum G; Pahor M; Alderman MH; Weiss NS
    JAMA; 2003 May; 289(19):2534-44. PubMed ID: 12759325
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Hypertrophic cardiomyopathy: place and limitations of medical therapy].
    Desnos M; Hagège A; Guérot C
    Arch Mal Coeur Vaiss; 1995 Apr; 88(4 Suppl):573-5. PubMed ID: 7487302
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.